NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I think the recent 10K was the first shot across the bow that Europe might take substantially longer. Then the change in the NICE timeline seemed to strongly confirm this. See my last two posts. This is all I can come up with. I think Linda Liau obtained her MBA for the very purpose of handling the important aspect of reimbursement. (For DCVax? I don't know, but that's what I'd assume)

Look, BMY's Opdivo has major problems with NICE's price structuring in Europe. For NWBO, in addition to price, they will also need to have manufacturing developed in Europe and put their best food forward on longevity results. Remember, this time delay regarding NICE does not show DCVax-L was rejected, but between needing manufacturing and highest price possible for commercial feasibility...well I'm repeating myself. Just guessing.